Drug Profile
Research programme: Cancer therapeutics - PUMC Pharmaceutical Company
Alternative Names: 801; AD1Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator PUMC Pharmaceutical Company
- Class Colchicum alkaloids
- Mechanism of Action DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Aug 2023 Discontinued - Preclinical for Cancer in China (PUMC Pharmaceutical pipeline)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in China (Injection)
- 06 Jan 2016 Preclinical trials in Cancer in China (unspecified route)